Dr. Perry has extensive experience in preclinical and clinical drug development. He is a venture capitalist currently with Bioscience Managers, a global venture capital firm, and previously with Bay City Capital LLC (2005-2012). Dr. Perry also currently serves as faculty at Houston Methodist and he is Adjunct Professor at the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus.

Dr. Perry has served in various pharmaceutical executive positions. From 2017 to 2022 he was CEO of Avita Medical, Inc., a regenerative medicine company based in Valencia, CA. From 1994-2000 and 2012-2017, he had various executive positions within Novartis, the US affiliate of Switzerland-based Novartis AG, a global pharmaceutical company. He served as CSO of Novartis’ Cell and Gene Therapy Unit (2014 to 2017); VP and Global Head of Stem Cell Therapy (2012 to 2014); President and CEO of both SyStemix Inc. and Genetic Therapy Inc., two wholly owned subsidiaries of Novartis Corp. (1997 to 2000), and VP of Regulatory Affairs for Novartis Pharma (previously Sandoz Pharmaceuticals, 1994-1997). Dr. Perry held various organizational leadership positions with various other companies from 2000-2012.

Dr. Perry serves on the Scientific Advisory Board of 7 Hills Pharma, a private clinical-stage pharmaceutical company; and is Chair of the Translational Medicine Advisory Board of the Houston Methodist Research Institute. He has also been on the board of 10 other companies.

Dr. Perry holds an Honors BS (Physics and Engineering) and a PhD (Biomedical Pharmacology) from the University of Guelph, Ontario, Canada. He has also earned a DVM (Doctor of Veterinary Medicine & Surgery) from Ontario Veterinary College and he is a graduate of the International Advanced Management Program at Harvard Business School.